DSGN241220P5000
- 0.25
- 0.000.00%
Design Therapeutics Newsroom
Design Therapeutics to Participate in Multiple Upcoming Investor Conferences
Cautious Optimism for Design Therapeutics Amid Promising Developments and Financial Challenges
RBC Capital Remains a Hold on Design Therapeutics (DSGN)
Design Therapeutics Reports Q3 EPS (23c), Consensus (24c)
Design Therapeutics | 10-Q: Q3 2024 Earnings Report
Design Therapeutics | 8-K: Design Therapeutics Announces Third Quarter 2024 Financial Results and Reviews Near-term Milestones for GeneTAC TM Portfolio
Earnings Flash (DSGN) DESIGN THERAPEUTICS Posts Q3 Loss $-0.23
Express News | Design Therapeutics Q3 Net Income USD -13.039 Million
Press Release: Design Therapeutics Announces Third Quarter 2024 Financial Results and Reviews Near-term Milestones for GeneTACTM Portfolio
We're Hopeful That Design Therapeutics (NASDAQ:DSGN) Will Use Its Cash Wisely
Design Therapeutics Gains 19%, Insider Trades Reap Benefit
Design Therapeutics to Participate in the 2024 Cantor Global Healthcare Conference
Wall Street Analysts Think Design Therapeutics (DSGN) Could Surge 39.72%: Read This Before Placing a Bet
Design Therapeutics: A Cautious Hold Amidst Financial Stability and Clinical Progress
Design Therapeutics Price Target Maintained With a $4.00/Share by RBC Capital
Design Therapeutics Analyst Ratings
RBC Capital Sticks to Their Hold Rating for Design Therapeutics (DSGN)
Express News | Design Therapeutics Inc : Leerink Partners Raises Target Price to $5.00 From $4.00
Design Therapeutics GAAP EPS of -$0.21
Design Therapeutics | 10-Q: Q2 2024 Earnings Report